IMMUNE EPITOPE DATABASE AND ANALYSIS PROGRAM
National Institutes of Health · NATIONAL INSTITUTES OF HEALTH NIAID
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation 75N93026C00001 in this department, oldest first.
- Mar 16, 2026 · this noticeAward NoticeLA JOLLA INSTITUTE FOR IMMUNOLOGY La Jolla CA 92037 USA · $24.3M
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Note the winner and the end of the period of performance for the recompete.
- Follow the agency to see the next notice for this work.
What the notice says
A competitive cost reimbursement, level of effort (term) type contract was awarded, for the period of performance of March 15, 2026 through December 14, 2026 (Base Period), and a total period of performance (including Base Period and all Options) of March 15, 2026 through December 14, 2030. Upon analysis of the type of work and all associated costs involved, a fixed-price type contract was not feasible due to the absence of precise specifications and difficulties in estimating costs with accuracy. Based upon the uncertainties involved, the Government would assume undue risk in attempting to fi… (show all)
t a relatively dynamic (science responsive and result-driven) requirement into a fixed-price environment. A fixed-price contract would be disadvantageous to the Government, since it does not provide the Government with the flexibility that is needed to responsibly shift with the evolving needs of the requirement. The award notice is in relation to Solicitation # 75N93024R00017.
Who won similar work
29 award notices on SAM.gov in the last 24 months. Matched by: Same office (NATIONAL INSTITUTES OF HEALTH NIAID), same product/service code (PSC) AN12.
Single-winner award sizes (17): middle half $2.6M to $48.0M, median $25.4M; range $10K to $48.0M.
| Winner | Awards | Value | Last |
|---|---|---|---|
| SIA PARTNERS U.S., INC. | 2 | $48.0M + 1 shared | Oct 7, 2026 |
| EMINENT SERVICES CORP | 2 | $32.9M + 1 shared | Jul 8, 2026 |
| PPD DEVELOPMENT LP | 1 | $48.0M | Oct 7, 2026 |
| ADVANCED BIOSCIENCE LABORATORIES, INC. | 1 | $48.0M | Oct 7, 2026 |
| BCG FEDERAL CORP. | 1 | $48.0M | Oct 7, 2026 |
| FISHER BIOSERVICES INC · $TMO · $42.9B | 1 | $48.0M | Oct 7, 2026 |
| AMERICAN TYPE CULTURE COLLECTION Manassas VA 20110 USA | 1 | $48.0M | Oct 7, 2026 |
| DUKE UNIVERSITY Durham NC 27705 USA | 1 | $28.3M | Mar 31, 2025 |
| Quality Biological, Inc | 1 | $25.4M | Apr 9, 2025 |
| ARISAN THERAPEUTICS INC | 1 | $23.9M | Aug 3, 2026 |
Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.
- $TMO reported $42.9B revenue in FY2025. The median single-winner award in these 17 past awards, $25.4M, is under 0.1% of that. 10-K
One award's total value against one year of revenue; many awards are paid over several years.
- Oct 7, 2026AMERICAN TYPE CULTURE COLLECTION Manassas VA 20110 USA$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASES
- Oct 7, 2026ADVANCED BIOSCIENCE LABORATORIES, INC.$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASES
- Oct 7, 2026PPD DEVELOPMENT LP$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASES
- Oct 7, 2026SIA PARTNERS U.S., INC.$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASES
- Oct 7, 2026BCG FEDERAL CORP.$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASES
- Oct 7, 2026FISHER BIOSERVICES INC$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASES
- Aug 17, 2026TCG GREENCHEM INC$49.7M (shared ceiling)Chemistry, Manufacturing and Controls and Related Services for Development of Drug Substances
- Aug 5, 2026CURIA GLOBAL INC$49.7M (shared ceiling)Chemistry, Manufacturing and Controls and Related Services for Development of Drug Substances
- Aug 5, 2026SOUTHWEST RESEARCH INSTITUTE San Antonio TX 78238 USA$49.7M (shared ceiling)Chemistry, Manufacturing and Controls and Related Services for Development of Drug Substances
- Aug 5, 2026TCG INC$49.7M (shared ceiling)Chemistry, Manufacturing and Controls and Related Services for Development of Drug Substances
Competitive landscape
For the 8 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 1 of these past winners lobbied Natl Institutes of Health (NIH) since 2024 (7 filings)
- 0 of their lobbyists list a past Natl Institutes of Health (NIH) job
- $64K from their corporate PACs since 2024 to members of House Committee on Appropriations, House Committee on Energy and Commerce, Senate Committee on Appropriations, Senate Committee on Health, Education, Labor, and Pensions
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 8 bills named on the past winners' lobbying filings
- 0 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
- 1 of the past winners are listed companies
- 0 insider buys and 7 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.